Global Growth Hormone Deficiency Market Research Report—Forecast till 2027

$4,450$6,250

Global Growth Hormone Deficiency Market is anticipated to exhibit a CAGR of 4.20% during the review period of 2020 to 2027, to surpass USD 5,243.3 Million by 2027.

Clear

Description

Growth Hormone Deficiency Market Overview

Global Growth Hormone Deficiency Market is anticipated to exhibit a CAGR of 4.20% during the review period of 2020 to 2027, to surpass USD 5,243.3 Million by 2027. Growth hormone deficiency is a disease caused by the inadequacy of growth hormones in the body. Growth hormone deficiency is an endocrine disease characterized by low or deficient secretion of growth hormone.

The global market growth is attributed to the rising prevalence of GHD, the growing launch of drugs by prominent market players, and growing awareness about the disease. Moreover, a growing engagement of major market players in the advancement of growth hormone products is expected to enhance the market growth during the review period.

The Global Growth Hormone Deficiency Market is estimated to register significant market growth during the review period owing to the rising number of individuals suffering from Growth Hormone Deficiency (GHD), increasing awareness regarding the effectiveness of growth hormone along with clinical trials focused on the safety and efficacy of GHD, and the changing lifestyle along with the growing prevalence of genetic disorders.

However, the high cost of treatment and increasing counterfeit products being used for the treatment are restraining the market growth. On the other hand, the collaboration of major players with small players, coupled with the rise in the innovation marked by prominent players, poses lucrative opportunities for the global growth hormone deficiency market.

Market Segmentation

Global Growth Hormone Deficiency Market has been classified into Brand, Application, Distribution Channel, and Route of Administration.
Global Growth Hormone Deficiency Market has been divided into various brands such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others.

Based on the application segment the global market has been classified into pediatric growth hormone deficiency, Turner syndrome, Idiopathic Short Stature (ISS), small for gestational age, adult growth hormone deficiency, Prader-Willi syndrome, and others.

In terms of route of administration, the global market has been categorized into subcutaneous, intravenous, and intramuscular.
Global Growth Hormone Market based on the distribution channel has been segmented into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

Regional Analysis

Global Growth Hormone Deficiency Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is divided into North America and Latin America. The Americas dominated the market in 2019 and is expected to command the market during the review period as well.

The regional market growth is driven by the factors such as the rising prevalence of growth hormone deficiency, increasing applications of the hormone, and increasing awareness about the effectiveness of the hormone in short stature.

The European growth hormone deficiency market has been further bifurcated into Eastern Europe and Western Europe. Western Europe market is spread across Germany, the UK, France, Italy, and Spain.

The European market is anticipated to register a substantial market of the global growth hormone deficiency owing to the increasing occurrences of growth hormone deficiencies, rising preference for growth hormones, and growing government expenditure for the healthcare sector.

Asia-Pacific is expected to be the fastest-growing market due to the rising healthcare expenditure and existence of the largest patient pool. The regional market growth is driven by the increasing investments by key market players in the region because of the growing demand.

The Middle East & Africa market is expected to register a steady market growth owing to the rising healthcare expenditure, increasing investments by major market players, and an increasing patient pool in the region.

Major Players

The Key Players in the Global Growth Hormone Deficiency Market include Novo Nordisk A/S, Eli Lily and Company, Novartis AG, Merck KGaA, and Pfizer.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

U.S Biosimilars Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
“1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION 14

2.2 SCOPE OF THE STUDY 14

2.3 RESEARCH OBJECTIVE 14

2.4 MARKET STRUCTURE 14

2.5 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY

3.1 DATA MINING 16

3.2 SECONDARY RESEARCH 17

3.3 PRIMARY RESEARCH 17

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 19

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY 25

4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY 25

4.2.3 GOVERNMENT INITIATIVES FOR GHD 25

4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS 25

4.3 RESTRAINTS 26

4.3.1 HIGH COST OF GHD TREATMENT 26

4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT 26

4.4 OPPORTUNITIES 27

4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS 27

4.5 CLINICAL TRIALS ANALYSIS 27

4.6 MEGATRENDS 31

4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 31

4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS 31

4.6.3 PRODUCTS UNDER DEVELOPMENT 31

4.7 MACROECONOMIC INDICATORS 33

4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES 33

4.9 LONG ACTING GROWTH HORMONES (LAGH) 36

4.9.1 OVERVIEW 36

4.9.2 DEVELOPMENT 36

4.9.3 UPCOMING PRODUCTS 37

4.9.4 TRENDS 38

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS 39

5.1.1 RESEARCH AND DEVELOPMENT 40

5.1.2 MANUFACTURING 40

5.1.3 DISTRIBUTION 40

5.1.4 MARKETING AND SALES 40

5.1.5 POST-SALES MONITORING 40

5.2 PORTER’S FIVE FORCES MODEL 41

5.2.1 THREAT OF NEW ENTRANTS 41

5.2.2 BARGAINING POWER OF SUPPLIERS 41

5.2.3 THREAT OF SUBSTITUTES 42

5.2.4 BARGAINING POWER OF BUYERS 42

5.2.5 RIVALRY 42

5.3 IMPACT OF COVID-19 43

5.3.1 OVERVIEW 43

5.3.2 IMPACT ON SUPPLY CHAIN 43

5.3.3 IMPACT ON PRODUCTION 43

5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2020) 44

6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND

6.1 OVERVIEW 47

6.2 NORDITROPIN 48

6.3 GENOTROPIN 48

6.4 HUMATROPE 49

6.5 SAIZEN 49

6.6 OMNITROPE 50

6.7 OTHERS 50

7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION

7.1 OVERVIEW 51

7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY 52

7.3 IDIOPATHIC SHORT STATURE 53

7.4 SMALL FOR GESTATIONAL AGE 53

7.5 TURNER SYNDROME 54

7.6 ADULT GROWTH HORMONE DEFICIENCY 54

7.7 PRADER-WILLI SYNDROME 55

7.8 OTHERS 55

8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW 56

8.2 SUBCUTANEOUS 57

8.3 INTRAMUSCULAR 58

8.4 INTRAVENOUS 58

9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW 60

9.2 HOSPITAL PHARMACIES 61

9.3 RETAIL PHARMACIES 62

9.4 CLINICS 62

9.5 E-COMMERCE WEBSITES 63

10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION

10.1 OVERVIEW 64

10.2 AMERICAS 65

10.2.1 NORTH AMERICA 68

10.2.1.1 US 71

10.2.1.2 CANADA 73

10.2.2 LATIN AMERICA 74

10.3 EUROPE 77

10.3.1 WESTERN EUROPE 79

10.3.1.1 GERMANY 82

10.3.1.2 FRANCE 84

10.3.1.3 UK 86

10.3.1.4 ITALY 88

10.3.1.5 SPAIN 89

10.3.1.6 REST OF WESTERN EUROPE 91

10.3.2 EASTERN EUROPE 93

10.4 ASIA-PACIFIC 96

10.4.1 JAPAN 98

10.4.2 CHINA 100

10.4.3 INDIA 102

10.4.4 AUSTRALIA 104

10.4.5 SOUTH KOREA 106

10.4.6 REST OF ASIA-PACIFIC 108

10.5 MIDDLE EAST & AFRICA 110

10.5.1 MIDDLE EAST 112

10.5.2 AFRICA 114

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 117

11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2020) 117

11.3 COMPETITIVE BENCHMARKING 119

11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 120

11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 121

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 121

11.6.1 EXPANSION 122

11.6.2 PRODUCT APPROVAL/FDA APPROVAL 122

12 APPENDIX

12.1 REFERENCES 123

12.2 RELATED REPORTS 123”